Literature DB >> 27190592

Discovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACs.

Jesus M Ontoria1, Giacomo Paonessa1, Simona Ponzi1, Federica Ferrigno1, Emanuela Nizi1, Ilaria Biancofiore1, Savina Malancona1, Rita Graziani1, David Roberts2, Paul Willis2, Alberto Bresciani1, Nadia Gennari1, Ottavia Cecchetti1, Edith Monteagudo1, Maria V Orsale1, Maria Veneziano1, Annalise Di Marco1, Antonella Cellucci1, Ralph Laufer1, Sergio Altamura1, Vincenzo Summa1, Steven Harper1.   

Abstract

The identification of a new series of P. falciparum growth inhibitors is described. Starting from a series of known human class I HDAC inhibitors a SAR exploration based on growth inhibitory activity in parasite and human cells-based assays led to the identification of compounds with submicromolar inhibition of P. falciparum growth (EC50 < 500 nM) and good selectivity over the activity of human HDAC in cells (up to >50-fold). Inhibition of parasital HDACs as the mechanism of action of this new class of selective growth inhibitors is supported by hyperacetylation studies.

Entities:  

Keywords:  4-arylimidazoles; Malaria; PfHDAC1; Plasmodium falciparum

Year:  2016        PMID: 27190592      PMCID: PMC4867480          DOI: 10.1021/acsmedchemlett.5b00468

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

1.  Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.

Authors:  Olaf Kinzel; Laura Llauger-Bufi; Giovanna Pescatore; Michael Rowley; Carsten Schultz-Fademrecht; Edith Monteagudo; Massimiliano Fonsi; Odalys Gonzalez Paz; Fabrizio Fiore; Christian Steinkühler; Philip Jones
Journal:  J Med Chem       Date:  2009-06-11       Impact factor: 7.446

2.  Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.

Authors:  Giuseppe Giannini; Gianfranco Battistuzzi; Davide Vignola
Journal:  Bioorg Med Chem Lett       Date:  2014-12-19       Impact factor: 2.823

3.  Chemical studies of histone acetylation. The occurrence of epsilon-N-acetyllysine in the f2a1 histone.

Authors:  E L Gershey; G Vidali; V G Allfrey
Journal:  J Biol Chem       Date:  1968-10-10       Impact factor: 5.157

Review 4.  HDAC inhibitors in parasitic diseases.

Authors:  Katherine T Andrews; Ashraful Haque; Malcolm K Jones
Journal:  Immunol Cell Biol       Date:  2011-11-29       Impact factor: 5.126

5.  Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.

Authors:  Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Enny Kenangalem; Kim A Piera; David P Fairlie; Emiliana Tjitra; Nicholas M Anstey; Kathy T Andrews; Ric N Price
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

Review 6.  Drug-resistant malaria - an insight.

Authors:  John E Hyde
Journal:  FEBS J       Date:  2007-09       Impact factor: 5.542

7.  Histone deacetylases play a major role in the transcriptional regulation of the Plasmodium falciparum life cycle.

Authors:  Balbir K Chaal; Archna P Gupta; Brigitta D Wastuwidyaningtyas; Yen-Hoon Luah; Zbynek Bozdech
Journal:  PLoS Pathog       Date:  2010-01-22       Impact factor: 6.823

8.  Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice.

Authors:  S Agbor-Enoh; C Seudieu; E Davidson; A Dritschilo; M Jung
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

9.  Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum.

Authors:  Guangan Hu; Ana Cabrera; Maya Kono; Sachel Mok; Balbir K Chaal; Silvia Haase; Klemens Engelberg; Sabna Cheemadan; Tobias Spielmann; Peter R Preiser; Tim-W Gilberger; Zbynek Bozdech
Journal:  Nat Biotechnol       Date:  2009-12-27       Impact factor: 54.908

10.  Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.

Authors:  Jessica A Engel; Amy J Jones; Vicky M Avery; Subathdrage D M Sumanadasa; Susanna S Ng; David P Fairlie; Tina Skinner-Adams; Katherine T Andrews
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-06-20       Impact factor: 4.077

View more
  9 in total

1.  Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.

Authors:  Dong Lu; Juan Yan; Lang Wang; Hongchun Liu; Limin Zeng; Minmin Zhang; Wenwen Duan; Yinchun Ji; Jingchen Cao; Meiyu Geng; Aijun Shen; Youhong Hu
Journal:  ACS Med Chem Lett       Date:  2017-07-18       Impact factor: 4.345

2.  Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.

Authors:  Alberto Bresciani; Jesus M Ontoria; Ilaria Biancofiore; Antonella Cellucci; Alina Ciammaichella; Annalise Di Marco; Federica Ferrigno; Alessandra Francone; Savina Malancona; Edith Monteagudo; Emanuela Nizi; Paola Pace; Simona Ponzi; Ilaria Rossetti; Maria Veneziano; Vincenzo Summa; Steven Harper
Journal:  ACS Med Chem Lett       Date:  2018-11-27       Impact factor: 4.345

3.  One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.

Authors:  Daniela Diedrich; Katharina Stenzel; Eva Hesping; Yevgeniya Antonova-Koch; Tamirat Gebru; Sandra Duffy; Gillian Fisher; Andrea Schöler; Stephan Meister; Thomas Kurz; Vicky M Avery; Elizabeth A Winzeler; Jana Held; Katherine T Andrews; Finn K Hansen
Journal:  Eur J Med Chem       Date:  2018-09-07       Impact factor: 6.514

4.  In silico identification of inhibitors against Plasmodium falciparum histone deacetylase 1 (PfHDAC-1).

Authors:  Amarjeet Kumar; Suman Kumar Dhar; Naidu Subbarao
Journal:  J Mol Model       Date:  2018-08-14       Impact factor: 1.810

5.  Exploration of thiaheterocyclic hHDAC6 inhibitors as potential antiplasmodial agents.

Authors:  Rob De Vreese; Carmen de Kock; Peter J Smith; Kelly Chibale; Matthias D'hooghe
Journal:  Future Med Chem       Date:  2017-03-06       Impact factor: 3.808

6.  Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria.

Authors:  Vijay Potluri; Radha K Shandil; R Gavara; Ganesh Sambasivam; Brice Campo; Sergio Wittlin; Shridhar Narayanan
Journal:  Malar J       Date:  2020-10-12       Impact factor: 2.979

7.  Epigenetic inhibitors target multiple stages of Plasmodium falciparum parasites.

Authors:  Nanika Coetzee; Hilde von Grüning; Daniel Opperman; Mariette van der Watt; Janette Reader; Lyn-Marié Birkholtz
Journal:  Sci Rep       Date:  2020-02-11       Impact factor: 4.379

Review 8.  Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis.

Authors:  Ehab Ghazy; Mohamed Abdelsalam; Dina Robaa; Raymond J Pierce; Wolfgang Sippl
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-10

9.  Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin-HDAC Inhibitor Hybrids as Multitarget Drugs.

Authors:  Lukas von Bredow; Thomas Martin Schäfer; Julian Hogenkamp; Maik Tretbar; Daniel Stopper; Fabian B Kraft; Julian Schliehe-Diecks; Andrea Schöler; Arndt Borkhardt; Sanil Bhatia; Jana Held; Finn K Hansen
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.